1. Deng L, Wojciech L, Gascoigne NR, Peng G, Tan KS. New insights into the interac-tions between Blastocystis, the gut microbio-ta, and host immunity. PLoS Pathog. 2021; 17(2):e1009253.
2. Naguib D, El-Gohary AH, Roellig D, et al. Molecular characterization of Cryptosporidi-um spp. and Giardia duodenalis in children in Egypt. Parasit Vectors. 2018; 11(1):403. https://doi.org/10.1186/s13071-018-2981-7.
3. Youssef AI, Uga S. Review of parasitic zoonoses in Egypt. Trop Med Health. 2013; 42:3-14. https://doi.org/10.10.2149/tmh.2013-23
4. de Lucio A, Amor-Aramendía A, Bailo B, et al. Prevalence and Genetic Diversity of Giardia duodenalis and Cryptosporidium spp. among School Children in a Rural Area of the Amhara Region, North-West Ethiopia. PLOS One. 2016; 11(7):e015999. https://doi.org/10.1371/journal.pone.0159992
5. Eassa SM, Ali HS, El Masry SA, Abd El-Fattah AH. Blastocystis hominis among im-munocompromised and immunocompe-tent children in Alexandria, Egypt. Ann Clin Lab Res. 2016; 4:92-8.
6. Sánchez A, Munoz M, Gómez N, et al. Molecular Epidemiology of Giardia, Blasto-cystis and Cryptosporidium among Indigenous Children from the Colombian Amazon Basin. Front Microbiol. 2017; 8:248. https://doi.org/10.3389/fmicb.2017.00248.
7. Abdo SM, El-Adawy H, Farag HF, El-Taweel HA, Elhadad H, El-Badry AA. De-tection and molecular identification of Blas-tocystis isolates from humans and cattle in northern Egypt. J Parasit Dis. 2021; 45:738-745. https://doi.org/10.1007/s12639-021-01354-5
8. Elhadad H, Abdo S, Tolba M, et al. Detec-tion of Giardia intestinalis assemblages A and B among children from three villages in the West Delta region, Egypt using as-semblage specific primers. J Parasit Dis. 2121; 45:655-663. https://doi.org/10.1007/s12639-020-01338-x.
9. Hamdy DA, Abd El Wahab WM, Senosy SA, Mabrouk AG. Blastocystis spp. and Giar-dia intestinalis co-infection profile in children suffering from acute diarrhea. J Parasit Dis. 2020; 44:88-98. https://doi.org/10.1007/s12639-019-01165-9
10. Dixon BR. Giardia duodenalis in humans and animals–Transmission and disease. Res Vet Sci. 2121;135:283-9. https://doi.org/10.1016/j.rvsc.2020.09.034
11. Rossignol JF. Cryptosporidium and Giardia: treatment options and prospects for new drugs. Exp Parasitol. 2010; 124:45-53. https://doi.org/10.1016/j.exppara.2009.07.005
12. Pasupuleti V, Escobedo AA, Deshpande A, Thota P, Roman Y, Hernandez AV. Ef-ficacy of 5-nitroimidazoles for the treat-ment of giardiasis: a systematic review of randomized controlled trials. PLoS Negl Tropl Dis. 2014; 8:e2733. https://doi.org/10.1371/journal.pntd.0002733
13. Sekar U, Shanthi M. Blastocystis: Consensus of treatment and controversies. Trop Par-asitol. 2013; 3:35. https://doi.org/10.4103/2229-5070.113901
14. Lalle M, Hanevik K. Treatment-refractory giardiasis: challenges and solutions. Infect Drug Resist. 2018; 11:1921. https://doi.org/10.2147/IDR.S141468
15. Nigam P, Kapoor K, Kumar A, Sarkari N, Gupta A. Clinical profile of giardiasis and comparison of its therapeutic response to metronidazole and tinidazole. J Assoc Physicians India. 1991; 39:613-5.
16. Cedillo‐Rivera R, Chávez B, Gonzá-lez‐Robles A, Tapia A, Yépez‐Mulia L. In vitro effect of nitazoxanide against Enta-moeba histolytica, Giardia intestinalis and Trichomonas vaginalis trophozoites. J Eukary-ot Microbiol. 2002; 49:201-8. https://doi.org/10.1111/j.1550-7408.2002.tb00523.x.
17. Mendoza D, Núñez FÁ, Escobedo ÁA, et al. Utilidad de 2 métodos coproparasito-lógicos y su empleo en un ensayo terapéu-tico antigiardiásico. Rev Cubana Med Trop. 2003; 55:174-8.
18. Roberts T, Ellis J, Harkness J, Marriott D, Stark D. Treatment failure in patients with chronic Blastocystis infection. J medl Micro-biol. 2014;63:252-7. https://doi.org/10.1099/jmm.0.065508-0
19. Gilles HM, Hoffman PS. Treatment of intestinal parasitic infections: a review of nitazoxanide. Trends Parasitol. 2002; 18:95-7. https://doi.org/10.1016/s1471-4922(01)02205-x
20. Galeh TM, Kazemi A, Mahami-Oskouei M, et al. Introducing nitazoxanide as a promising alternative treatment for symp-tomatic to metronidazole-resistant giardia-sis in clinical isolates. Asian Pac J Trop Med. 2016; 9:887-92. https://doi.org/10.1016/j.apjtm.2016.07.013.
21. Ibrahim AN. Comparison of in vitro ac-tivity of metronidazole and garlic-based product (Tomex®) on Trichomonas vaginalis. Parasitol Res. 2013; 112(5):2063-7. doi: 10.1007/s00436-013-3367-6. Epub 2013 Mar 2. PMID: 2345594
22. Yakoob J, Abbas Z, Beg MA, et al. In vitro sensitivity of Blastocystis hominis to gar-lic, ginger, white cumin, and black pepper used in diet. Parasitol Res. 2011; 109:379-85. https://doi.org/10.1007/s00436-011-2265-z.
23. Argüello-García R, de la Vega-Arnaud M, Loredo-Rodríguez IJ, EA, et al. Activity of thioallyl compounds from garlic against Giardia duodenalis trophozoites and in ex-perimental giardiasis. Front Cell Infect Mi-crobiol. 2018; 8:353. https://doi.org/10.3389/fcimb.2018.00353
24. Soffar SA, Mokhtar GM. Evaluation of the antiparasitic effect of aqueous garlic (Allium sativum) extract in hymenolepiasis nana and giardiasis. J Egypt Soc Parasitol. 1991; 21:497-502.
25. Coyle CM, Varughese J, Weiss LM, Tan-owitz HB. Blastocystis: to treat or not to treat. Clin Infect Dis. 2012; 54:105-10. https://doi.org/10.1093/cid/cir810
26. Escobedo A, Alvarez G, González M, et al. The treatment of giardiasis in children: single-dose tinidazole compared with 3 days of nitazoxanide. Ann Trop Med Par-asitol. 2008; 102:199-207. https://doi.org/10.1179/136485908X267894
27. Nagel R, Bielefeldt-Ohmann H, Traub R. Clinical pilot study: efficacy of triple antibi-otic therapy in Blastocystis positive irritable bowel syndrome patients. Gut Pathog. 2014; 6:1-9. https://doi.org/10.1186/s13099-014-0034-0
28. Dunn LA, Boreham PF. The in-vitro activ-ity of drugs against Blastocystis hominis. J An-timicrob Chemother. Apr. 1991; 27:507-16. doi: https://doi.org/10.1093/jac/27.4.507.
29. Rossignol JF, Kabil SM, Said M, Samir H, Younis AM. Effect of nitazoxanide in per-sistent diarrhea and enteritis associated with Blastocystis hominis. Clin Gastroenterol Hepatol. 2005;3:987-91. https://doi.org/10.1016/s1542-3565(05)00427-1.
30. Ibrahim HS, Salem AI, Ahmed NMAE-R, El-Taweel HA. Pre-and post-treatment evaluation of intestinal inflammation in Gi-ardia and Blastocystis infected children: a community-based study. J Parasit Dis. 2021; 45:1026-1033. https://doi.org/10.1007/s12639-021-01398-7
31. Rossignol JF, Ayoub A, Ayers MS. Treat-ment of diarrhea caused by Giardia intesti-nalis and Entamoeba histolytica or E. dispar: A randomized, double‐blind, place-bo‐controlled study of nitazoxanide. J In-fect Dis. 2001; 184:381-4. https://doi.org/10.1086/322038
32. Diaz E, Mondragon J, Ramirez E, Bernal R. Epidemiology and control of intestinal parasites with nitazoxanide in children in Mexico. Am J Trop Med Hyg. 2003; 68:384-5.
33. Tejman-Yarden N, Millman M, Lauwaet T, et al. Impaired parasite attachment as fit-ness cost of metronidazole resistance in Giardia lamblia. Antimicrob Agents Chemother. 2011; 55:4643-51. https://doi.org/10.1128/AAC.00384-11
34. Bhagyalakshmi N, Thimmaraju R, Venka-tachalam L, Murthy KC, Sreedhar R. Nutraceutical applications of garlic and the intervention of biotechnology. Crit Rev Food Sci Nutr. 2005; 45:607-21. https://doi.org/10.1080/10408390500455508.
35. Harris JC, Plummer S, Turner MP, Lloyd D. The microaerophilic flagellate Giardia in-testinalis: Allium sativum (garlic) is an effec-tive antigiardial. Microbiology. 2000; 146:3119-27. https://doi.org/10.1099/00221287-146-12-3119
36. Pengsaa K, Sirivichayakul C, Pojjaroen-Anant C, Nimnual S, Wisetsing P. Albend-azole treatment for Giardia intestinalis infec-tions in school children. Southeast Asian J Trop Med Public Health. 1999; 30:78-83.
37. Cañete R, Escobedo AA, Elena González M, Almirall P, Cantelar N. A randomized, controlled, open-label trial of a single day of mebendazole versus a single dose of tinidazole in the treatment of giardiasis in children. Curr Med Res Opin. 2006; 22:2131-6.
38. Halliez MC, Buret AG. Extra-intestinal and long term consequences of Giardia duode-nalis infections. World J Gastroenterol. 2013; 19: 8974-8985.
39. Mørch K, Hanevik K. Giardiasis treat-ment: an update with a focus on refractory disease. Curr Opin Infect Dis. 2020; 33: 355-364.